Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotska sredstva - prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 za hemodinamski nestabilne ТЭЛА pacijenata). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 i 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - repaglinid - tableta - urbroj: svaka tableta sadrži 0,5 mg repaglinida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - repaglinid - tableta - urbroj: svaka tableta sadrži 1 mg repaglinida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - repaglinid - tableta - urbroj: svaka tableta sadrži 2 mg repaglinida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - cinitapridhidrogentartarat - tableta - urbroj: svaka tableta sadrži 1 mg cinitaprida (u obliku cinitapridhidrogentartarata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - pioglitazonklorid - tableta - 15 mg - urbroj: jedna tableta sadrži 15 mg pioglitazona (u obliku klorida)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - pioglitazonklorid - tableta - 30 mg - urbroj: jedna tableta sadrži 30 mg pioglitazona (u obliku klorida)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - pioglitazonklorid - tableta - 45 mg - urbroj: jedna tableta sadrži 45 mg pioglitazona (u obliku klorida)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - pioglitazonklorid metforminklorid - filmom obložena tableta - 15 mg + 850 mg - urbroj: jedna tableta sadrži 15 mg pioglitazona (u obliku klorida) i 850 mg metforminklorida